co-occurred with neuronal loss and mitochondrial dysfunction. Proteomic analyses further highlighted increased levels of neuroinflammation and mitochondrial impairment markers, including SNCA, GPNMB, and LGALS3, some of which may serve as biomarkers of disease severity. These findings offer critical insights into PD's molecular pathogenesis and identify potential candidates for further functional validation and therapeutic intervention.
Kim et al. (Thu,) studied this question.